

28 *Be it enacted by the Legislature of the state of Utah:*

29 Section 1. Section **58-37-4** is amended to read:

30 **58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings**
31 **required -- Specific substances included in schedules.**

32 (1) There are established five schedules of controlled substances known as Schedules I,
33 II, III, IV, and V which consist of substances listed in this section.

34 (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by
35 the official name, common or usual name, chemical name, or brand name designated:

36 (a) Schedule I:

37 (i) Unless specifically excepted or unless listed in another schedule, any of the
38 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
39 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
40 chemical designation:

41 (A) Acetyl-alpha-methylfentanyl

42 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

43 (B) Acetylmethadol;

44 (C) Allylprodine;

45 (D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
46 levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

47 (E) Alphameprodine;

48 (F) Alphamethadol;

49 (G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
50 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

51 (H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
52 piperidinyl]-N-phenylpropanamide);

53 (I) Benzylpiperazine;

54 (J) Benzethidine;

55 (K) Betacetylmethadol;

56 (L) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
57 piperidinyl]-N-phenylpropanamide);

58 (M) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-

- 59 phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
- 60 (N) Betameprodine;
- 61 (O) Betamethadol;
- 62 (P) Betaprodine;
- 63 (Q) Clonitazene;
- 64 (R) Dextromoramide;
- 65 (S) Diampromide;
- 66 (T) Diethylthiambutene;
- 67 (U) Difenoxin;
- 68 (V) Dimenoxadol;
- 69 (W) Dimepheptanol;
- 70 (X) Dimethylthiambutene;
- 71 (Y) Dioxaphetyl butyrate;
- 72 (Z) Dipipanone;
- 73 (AA) Ethylmethylthiambutene;
- 74 (BB) Etonitazene;
- 75 (CC) Etoxidine;
- 76 (DD) Furethidine;
- 77 (EE) Hydroxypethidine;
- 78 (FF) Ketobemidone;
- 79 (GG) Levomoramide;
- 80 (HH) Levophenacetylmorphan;
- 81 (II) Morpheridine;
- 82 (JJ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 83 (KK) Noracymethadol;
- 84 (LL) Norlevorphanol;
- 85 (MM) Normethadone;
- 86 (NN) Norpipanone;
- 87 (OO) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
- 88 propanamide;
- 89 (PP) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);

- 90 (QQ) Phenadoxone;
- 91 (RR) Phenampromide;
- 92 (SS) Phenomorphan;
- 93 (TT) Phenoperidine;
- 94 (UU) Piritramide;
- 95 (VV) Proheptazine;
- 96 (WW) Properidine;
- 97 (XX) Propiram;
- 98 (YY) Racemoramide;
- 99 (ZZ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
- 100 (AAA) Tilidine;
- 101 (BBB) Trimeperidine;
- 102 (CCC) 3-methylfentanyl, including the optical and geometric isomers
103 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
104 (DDD) 3-methylthiofentanyl
105 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
- 106 (ii) Unless specifically excepted or unless listed in another schedule, any of the
107 following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
108 salts, isomers, and salts of isomers is possible within the specific chemical designation:
- 109 (A) Acetorphine;
- 110 (B) Acetyldihydrocodeine;
- 111 (C) Benzylmorphine;
- 112 (D) Codeine methylbromide;
- 113 (E) Codeine-N-Oxide;
- 114 (F) Cyprenorphine;
- 115 (G) Desomorphine;
- 116 (H) Dihydromorphine;
- 117 (I) Drotebanol;
- 118 (J) Etorphine (except hydrochloride salt);
- 119 (K) Heroin;
- 120 (L) Hydromorphanol;

- 121 (M) Methyldesorphine;
122 (N) Methylhydromorphine;
123 (O) Morphine methylbromide;
124 (P) Morphine methylsulfonate;
125 (Q) Morphine-N-Oxide;
126 (R) Myrophine;
127 (S) Nicocodeine;
128 (T) Nicomorphine;
129 (U) Normorphine;
130 (V) Pholcodine; and
131 (W) Thebacon.
- 132 (iii) Unless specifically excepted or unless listed in another schedule, any material,
133 compound, mixture, or preparation which contains any quantity of the following hallucinogenic
134 substances, or which contains any of their salts, isomers, and salts of isomers when the
135 existence of the salts, isomers, and salts of isomers is possible within the specific chemical
136 designation; as used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and
137 geometric isomers:
- 138 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
139 α -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;
140 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
141 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;
142 (C) 4-bromo-2,5-~~dimethoxyphenethylamine~~dimethoxyphenethylamine, some trade or
143 other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B,
144 Nexus;
145 (D) 2,5-dimethoxyamphetamine, some trade or other names:
146 2,5-dimethoxy- α -methylphenethylamine; 2,5-DMA;
147 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
148 (F) 4-methoxyamphetamine, some trade or other names:
149 4-methoxy- α -methylphenethylamine; paramethoxyamphetamine, PMA;
150 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
151 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:

- 152 4-methyl-2,5-dimethoxy- α -methylphenethylamine; "DOM"; and "STP";
- 153 (I) 3,4-methylenedioxy amphetamine;
- 154 (J) 3,4-methylenedioxymethamphetamine (MDMA);
- 155 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
- 156 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
- 157 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
- 158 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
- 159 (M) 3,4,5-trimethoxy amphetamine;
- 160 (N) Bufotenine, some trade and other names:
- 161 3-(β -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
- 162 N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
- 163 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
- 164 (P) Dimethyltryptamine, some trade or other names: DMT;
- 165 (Q) Ibogaine, some trade and other names:
- 166 7-Ethyl-6,6 β ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
- 167 [5,4-b] indole; Tabernanthe iboga;
- 168 (R) Lysergic acid diethylamide;
- 169 (S) Marijuana;
- 170 (T) Mescaline;
- 171 (U) Parahexyl, some trade or other names:
- 172 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
- 173 (V) Peyote, meaning all parts of the plant presently classified botanically as
- 174 *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from
- 175 any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
- 176 preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
- 177 (W) N-ethyl-3-piperidyl benzilate;
- 178 (X) N-methyl-3-piperidyl benzilate;
- 179 (Y) Psilocybin;
- 180 (Z) Psilocyn;
- 181 (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus *Cannabis*
- 182 (*cannabis* plant), as well as synthetic equivalents of the substances contained in the *cannabis*

183 plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives,
184 and their isomers with similar chemical structure and pharmacological activity to those
185 substances contained in the plant, such as the following: Δ^1 cis or trans tetrahydrocannabinol,
186 and their optical isomers Δ^6 cis or trans tetrahydrocannabinol, and their optical isomers $\Delta^3,4$
187 cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
188 substances is not internationally standardized, compounds of these structures, regardless of
189 numerical designation of atomic positions covered;

190 (BB) Ethylamine analog of phencyclidine, some trade or other names:

191 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
192 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;

193 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:

194 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

195 (DD) Thiophene analog of phencyclidine, some trade or other names:

196 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and

197 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.

198 (iv) Unless specifically excepted or unless listed in another schedule, any material
199 compound, mixture, or preparation which contains any quantity of the following substances
200 having a depressant effect on the central nervous system, including its salts, isomers, and salts
201 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
202 specific chemical designation:

203 (A) Mecloqualone; and

204 (B) Methaqualone.

205 (v) Any material, compound, mixture, or preparation containing any quantity of the
206 following substances having a stimulant effect on the central nervous system, including their
207 salts, isomers, and salts of isomers:

208 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
209 4,5-dihydro-5-phenyl-2-oxazolamine;

210 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
211 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;

212 (C) Fenethylamine;

213 (D) Methcathinone, some other names: 2-(methylamino)-propionophenone;

- 214 alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
- 215 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
- 216 methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
- 217 optical isomers;
- 218 (E) (\pm)cis-4-methylaminorex ((\pm)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 219 (F) N-ethylamphetamine; and
- 220 (G) N,N-dimethylamphetamine, also known as
- 221 N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
- 222 (vi) Any material, compound, mixture, or preparation which contains any quantity of
- 223 the following substances, including their optical isomers, salts, and salts of isomers, subject to
- 224 temporary emergency scheduling:
- 225 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
- 226 (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
- 227 (vii) Unless specifically excepted or unless listed in another schedule, any material,
- 228 compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
- 229 (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
- 230 (b) Schedule II:
- 231 (i) Unless specifically excepted or unless listed in another schedule, any of the
- 232 following substances whether produced directly or indirectly by extraction from substances of
- 233 vegetable origin, or independently by means of chemical synthesis, or by a combination of
- 234 extraction and chemical synthesis:
- 235 (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
- 236 opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone,
- 237 and their respective salts, but including:
- 238 (I) Raw opium;
- 239 (II) Opium extracts;
- 240 (III) Opium fluid;
- 241 (IV) Powdered opium;
- 242 (V) Granulated opium;
- 243 (VI) Tincture of opium;
- 244 (VII) Codeine;

- 245 (VIII) Ethylmorphine;
- 246 (IX) Etorphine hydrochloride;
- 247 (X) Hydrocodone;
- 248 (XI) Hydromorphone;
- 249 (XII) Metopon;
- 250 (XIII) Morphine;
- 251 (XIV) Oxycodone;
- 252 (XV) Oxymorphone; and
- 253 (XVI) Thebaine;
- 254 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
- 255 identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
- 256 substances may not include the isoquinoline alkaloids of opium;
- 257 (C) Opium poppy and poppy straw;
- 258 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
- 259 any salt, compound, derivative, or preparation which is chemically equivalent or identical with
- 260 any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,
- 261 and salts of isomers and derivatives, whether derived from the coca plant or synthetically
- 262 produced, except the substances may not include decocainized coca leaves or extraction of coca
- 263 leaves, which extractions do not contain cocaine or ecgonine; and
- 264 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
- 265 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
- 266 (ii) Unless specifically excepted or unless listed in another schedule, any of the
- 267 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and
- 268 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
- 269 chemical designation, except dextrorphan and levopropoxyphene:
- 270 (A) Alfentanil;
- 271 (B) Alphaprodine;
- 272 (C) Anileridine;
- 273 (D) Bezitramide;
- 274 (E) Bulk dextropropoxyphene (nondosage forms);
- 275 (F) Carfentanil;

- 276 (G) Dihydrocodeine;
- 277 (H) Diphenoxylate;
- 278 (I) Fentanyl;
- 279 (J) Isomethadone;
- 280 (K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol,
- 281 levomethadyl acetate, or LAAM;
- 282 (L) Levomethorphan;
- 283 (M) Levorphanol;
- 284 (N) Metazocine;
- 285 (O) Methadone;
- 286 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
- 287 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
- 288 acid;
- 289 (R) Pethidine (meperidine);
- 290 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 291 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 292 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 293 (V) Phenazocine;
- 294 (W) Piminodine;
- 295 (X) Racemethorphan;
- 296 (Y) Racemorphan;
- 297 (Z) Remifentanyl; and
- 298 (AA) Sufentanyl.
- 299 (iii) Unless specifically excepted or unless listed in another schedule, any material,
- 300 compound, mixture, or preparation which contains any quantity of the following substances
- 301 having a stimulant effect on the central nervous system:
- 302 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 303 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
- 304 (C) Phenmetrazine and its salts; and
- 305 (D) Methylphenidate.
- 306 (iv) Unless specifically excepted or unless listed in another schedule, any material,

307 compound, mixture, or preparation which contains any quantity of the following substances
308 having a depressant effect on the central nervous system, including its salts, isomers, and salts
309 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
310 specific chemical designation:

311 (A) Amobarbital;

312 (B) Glutethimide;

313 (C) Pentobarbital;

314 (D) Phencyclidine;

315 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and

316 1-piperidinocyclohexanecarbonitrile (PCC); and

317 (F) Secobarbital.

318 (v) (A) Unless specifically excepted or unless listed in another schedule, any material,
319 compound, mixture, or preparation which contains any quantity of Phenylacetone.

320 (B) Some of these substances may be known by trade or other names:

321 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.

322 (vi) Nabilone, another name for nabilone:

323 (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,

324 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.

325 (c) Schedule III:

326 (i) Unless specifically excepted or unless listed in another schedule, any material,
327 compound, mixture, or preparation which contains any quantity of the following substances
328 having a stimulant effect on the central nervous system, including its salts, isomers whether
329 optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers,
330 and salts of isomers is possible within the specific chemical designation:

331 (A) Those compounds, mixtures, or preparations in dosage unit form containing any
332 stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were
333 listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the
334 Code of Federal Regulations, and any other drug of the quantitative composition shown in that
335 list for those drugs or which is the same except that it contains a lesser quantity of controlled
336 substances;

337 (B) Benzphetamine;

- 338 (C) Chlorphentermine;
- 339 (D) Clortermine; and
- 340 (E) Phendimetrazine.

341 (ii) Unless specifically excepted or unless listed in another schedule, any material,
342 compound, mixture, or preparation which contains any quantity of the following substances
343 having a depressant effect on the central nervous system:

344 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
345 pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients
346 which are not listed in any schedule;

347 (B) Any suppository dosage form containing amobarbital, secobarbital, or
348 pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug
349 Administration for marketing only as a suppository;

350 (C) Any substance which contains any quantity of a derivative of barbituric acid or any
351 salt of any of them;

352 (D) Chlorhexadol;

353 (E) Buprenorphine;

354 (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
355 isomers, and salts of isomers, for which an application is approved under the federal Food,
356 Drug, and Cosmetic Act, Section 505;

357 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
358 \pm -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;

359 (H) Lysergic acid;

360 (I) Lysergic acid amide;

361 (J) Methyprylon;

362 (K) Sulfondiethylmethane;

363 (L) Sulfonethylmethane;

364 (M) Sulfonmethane; and

365 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
366 tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
367 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
368 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,

369 flupyrzapon.

370 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
371 U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
372 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
373 (-)-delta-9-(trans)-tetrahydrocannabinol.

374 (iv) Nalorphine.

375 (v) Unless specifically excepted or unless listed in another schedule, any material,
376 compound, mixture, or preparation containing limited quantities of any of the following
377 narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:

378 (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
379 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of
380 opium;

381 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
382 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
383 therapeutic amounts;

384 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
385 than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline
386 alkaloid of opium;

387 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
388 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
389 recognized therapeutic amounts;

390 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
391 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
392 therapeutic amounts;

393 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
394 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
395 recognized therapeutic amounts;

396 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
397 more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
398 recognized therapeutic amounts; and

399 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with

400 one or more active, non-narcotic ingredients in recognized therapeutic amounts.

401 (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids
402 including any of the following or any isomer, ester, salt, or derivative of the following that
403 promotes muscle growth:

- 404 (A) Boldenone;
- 405 (B) Chlorotestosterone (4-chlortestosterone);
- 406 (C) Clostebol;
- 407 (D) Dehydrochlormethyltestosterone;
- 408 (E) Dihydrotestosterone (4-dihydrotestosterone);
- 409 (F) Drostanolone;
- 410 (G) Ethylestrenol;
- 411 (H) Fluoxymesterone;
- 412 (I) Formebolone (formebolone);
- 413 (J) Mesterolone;
- 414 (K) Methandienone;
- 415 (L) Methandranone;
- 416 (M) Methandriol;
- 417 (N) Methandrostenolone;
- 418 (O) Methenolone;
- 419 (P) Methyltestosterone;
- 420 (Q) Mibolerone;
- 421 (R) Nandrolone;
- 422 (S) Norethandrolone;
- 423 (T) Oxandrolone;
- 424 (U) Oxymesterone;
- 425 (V) Oxymetholone;
- 426 (W) Stanolone;
- 427 (X) Stanozolol;
- 428 (Y) Testolactone;
- 429 (Z) Testosterone; and
- 430 (AA) Trenbolone.

431 (vii) Anabolic steroids expressly intended for administration through implants to cattle
432 or other nonhuman species, and approved by the Secretary of Health and Human Services for
433 use, may not be classified as a controlled substance.

434 (d) Schedule IV:

435 (i) Unless specifically excepted or unless listed in another schedule, any material,
436 compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
437 less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.

438 (ii) Unless specifically excepted or unless listed in another schedule, any material,
439 compound, mixture, or preparation which contains any quantity of the following substances,
440 including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
441 salts of isomers is possible within the specific chemical designation:

442 (A) Alprazolam;

443 (B) Barbital;

444 (C) Bromazepam;

445 (D) Butorphanol;

446 (E) Camazepam;

447 (F) Carisoprodol;

448 (G) Chloral betaine;

449 (H) Chloral hydrate;

450 (I) Chlordiazepoxide;

451 (J) Clobazam;

452 (K) Clonazepam;

453 (L) Clorazepate;

454 (M) Clotiazepam;

455 (N) Cloxazolam;

456 (O) Delorazepam;

457 (P) Diazepam;

458 (Q) Dichloralphenazone;

459 (R) Estazolam;

460 (S) Ethchlorvynol;

461 (T) Ethinamate;

- 462 (U) Ethyl loflazepate;
- 463 (V) Fludiazepam;
- 464 (W) Flunitrazepam;
- 465 (X) Flurazepam;
- 466 (Y) Halazepam;
- 467 (Z) Haloxazolam;
- 468 (AA) Ketazolam;
- 469 (BB) Loprazolam;
- 470 (CC) Lorazepam;
- 471 (DD) Lormetazepam;
- 472 (EE) Mebutamate;
- 473 (FF) Medazepam;
- 474 (GG) Meprobamate;
- 475 (HH) Methohexital;
- 476 (II) Methylphenobarbital (mephobarbital);
- 477 (JJ) Midazolam;
- 478 (KK) Nimetazepam;
- 479 (LL) Nitrazepam;
- 480 (MM) Nordiazepam;
- 481 (NN) Oxazepam;
- 482 (OO) Oxazolam;
- 483 (PP) Paraldehyde;
- 484 (QQ) Pentazocine;
- 485 (RR) Petrichloral;
- 486 (SS) Phenobarbital;
- 487 (TT) Pinazepam;
- 488 (UU) Prazepam;
- 489 (VV) Quazepam;
- 490 (WW) Temazepam;
- 491 (XX) Tetrazepam;
- 492 (YY) Triazolam;

493 (ZZ) Zaleplon; and

494 (AAA) Zolpidem.

495 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
496 any quantity of the following substances, including its salts, isomers whether optical, position,
497 or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
498 isomers is possible.

499 (iv) Unless specifically excepted or unless listed in another schedule, any material,
500 compound, mixture, or preparation which contains any quantity of the following substances
501 having a stimulant effect on the central nervous system, including its salts, isomers whether
502 optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,
503 isomers, and salts of isomers is possible within the specific chemical designation:

504 (A) Cathine ((+)-norpseudoephedrine);

505 (B) Diethylpropion;

506 (C) Fencamfamine;

507 (D) Fenproporex;

508 (E) Mazindol;

509 (F) Mefenorex;

510 (G) Modafinil;

511 (H) Pemoline, including organometallic complexes and chelates thereof;

512 (I) Phentermine;

513 (J) Pipradrol;

514 (K) Sibutramine; and

515 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

516 (v) Unless specifically excepted or unless listed in another schedule, any material,
517 compound, mixture, or preparation which contains any quantity of dextropropoxyphene
518 (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.

519 (e) Schedule V: Any compound, mixture, or preparation containing any of the
520 following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous
521 base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in
522 sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal
523 qualities other than those possessed by the narcotic drug alone:

- 524 (i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
- 525 (ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
- 526 grams;
- 527 (iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
- 528 grams;
- 529 (iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
- 530 atropine sulfate per dosage unit;
- 531 (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
- 532 (vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
- 533 atropine sulfate per dosage unit; and
- 534 (vii) unless specifically exempted or excluded or unless listed in another schedule, any
- 535 material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant
- 536 effect on the central nervous system, including its salts, isomers, and salts of isomers.

537 Section 2. Section **58-37-4.2** is amended to read:

538 **58-37-4.2. Listed controlled substances.**

539 The following substances, their analogs, homologs, and synthetic equivalents are listed

540 controlled substances:

- 541 (1) AB-001;
- 542 (2) AKB48;
- 543 (3) alpha-Pyrrolidinovalerophenone (alpha-PVP);
- 544 [(+)] (4) AM-694; 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone;
- 545 (5) AM-1248;
- 546 [(2)] (6) AM-2201; 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
- 547 (7) AM-2233;
- 548 (8) AM-679;
- 549 (9) A796,260;
- 550 (10) Butylone;
- 551 [(3)] (11) CP 47,497 and its C6, C8, and C9 homologs;
- 552 2-[(1R,3S)-3-hydroxycyclohexyl] -5-(2-methyloctan-2-yl)phenol;
- 553 (12) Diisopropyltryptamine (DiPT);
- 554 (13) Ethylone;

- 555 (14) Fluoroisocathinone;
556 (15) Fluoromethamphetamine;
557 [~~(4)~~] (16) Fluoromethcathinone;
558 [~~(5)~~] (17) HU-210;
559 (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
560 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
561 [~~(6)~~] (18) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
562 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
563 [~~(7)~~] (19) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
564 [~~(8)~~] (20) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone { also known as
565 1-Pentyl-3-(1-naphthoyl)indole};
566 [~~(9)~~] (21) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
567 [~~(10)~~] (22) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone { also known as
568 1-Butyl-3-(1-naphthoyl)indole};
569 [~~(11)~~] (23) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
570 [~~(12)~~] (24) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
571 [~~(13)~~] (25) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
572 [~~(14)~~] (26) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;
573 [~~(15)~~] (27) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;
574 [~~(16)~~] (28) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
575 [~~(17)~~] (29) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
576 [~~(18)~~] (30) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
577 (31) MAM-2201;
578 (32) Methoxetamine;
579 (33) Naphyrone;
580 (34) Pentedrone;
581 (35) Pentylone;
582 [~~(19)~~] (36) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;
583 [~~(20)~~] (37) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole { also
584 known as BTW-8 and SR-18};
585 (38) STS-135;

- 586 (39) UR-144;
- 587 (40) UR-144 N-(5-chloropentyl) analog;
- 588 (41) XLR11;
- 589 (42) 2C-C;
- 590 (43) 2C-D;
- 591 (44) 2C-E;
- 592 (45) 2C-H;
- 593 (46) 2C-I;
- 594 (47) 2C-N;
- 595 (48) 2C-P;
- 596 (49) 2C-T-2;
- 597 (50) 2C-T-4;
- 598 (51) 2NE1;
- 599 (52) 25I-NBOMe;
- 600 (53) 2,5-Dimethoxy-4-chloroamphetamine (DOC);
- 601 [~~(21)~~] (54) 4-methylmethcathinone {also known as mephedrone};
- 602 [~~(22)~~] (55) 3,4-methylenedioxypyrovalerone {also known as MDPV};
- 603 [~~(23)~~] (56) 3,4-Methylenedioxymethcathinone {also known as methylone}; [and]
- 604 [~~(24)~~] (57) 4-methoxymethcathinone[-];
- 605 (58) 4-Methyl-alpha-pyrrolidinopropiophenone;
- 606 (59) 4-Methylethcathinone;
- 607 (60) 5-Iodo-2-aminoindane (5-IAI); and
- 608 (61) 5-MeO-DALT.

Legislative Review Note
as of 11-15-12 3:59 PM

Office of Legislative Research and General Counsel